Treatment of metastatic melanoma: an overview.
Treatment of metastatic melanoma: an overview.
复制标题
DOI：
--
复制
发表时间：
2009-05
期刊：
影响因子：
3.5
通讯作者：
S. Bhatia;S. Tykodi;John A Thompson
中科院分区：
文献类型：
--
作者：
S. Bhatia;S. Tykodi;John A Thompson
转移性黑色素瘤患者的10年生存率低于10%。虽然手术和放射治疗在转移性疾病的治疗中发挥作用，但全身治疗是大多数患者的主要治疗方法。单药化疗耐受性良好，但反应率仅为5%至20%。联合化疗和生物化疗可能会提高客观反应率，但不能延长生存期，并与更大的毒性相关。免疫治疗方法，如高剂量白细胞介素-2与一小部分患者的持久反应有关。在这篇文章中，我们回顾了转移性黑色素瘤的治疗，包括有前途的研究方法。
The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although surgery and radiation therapy have a role in the treatment of metastatic disease, systemic therapy is the mainstay of treatment for most patients. Single-agent chemotherapy is well tolerated but is associated with response rates of only 5% to 20%. Combination chemotherapy and biochemotherapy may improve objective response rates but do not extend survival and are associated with greater toxicity. Immunotherapeutic approaches such as high-dose interleukin-2 are associated with durable responses in a small percentage of patients. In this article, we review the treatments for metastatic melanoma including promising investigational approaches.